Overall rank 151 · Score 103 · 2022 Jun
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
The lancet. Diabetes & endocrinology
Randomized trialAI-recommended Tier AType 2 diabetesSafetyDiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 152 · Score 103 · 2022 Sep 1
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity.
JAMA network open
Randomized trialAI-recommended Tier AWeight loss & obesityKidneyReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 153 · Score 103 · 2022 Dec 15
Once-Weekly Semaglutide in Adolescents with Obesity.
The New England journal of medicine
Randomized trialAI-recommended Tier AWeight loss & obesitySafetyPediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 154 · Score 103 · 2024 Jul
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
Diabetologia
Meta-analysisAI-recommended Tier AType 2 diabetesSafety
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 155 · Score 103 · 2024 Sep
Semaglutide and heart failure: Updated meta-analysis.
Current problems in cardiology
Meta-analysisAI-recommended Tier AHeart failureReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 156 · Score 103 · 2024 Nov
Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis.
Obesity reviews : an official journal of the International Association for the Study of Obesity
Meta-analysisAI-recommended Tier AWeight loss & obesityDiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 157 · Score 103 · 2022 Feb 22
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.
Circulation
Randomized trialAI-recommended Tier ACardiovascularKidney
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 158 · Score 103 · 2022 Sep
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
Journal of hepatology
Randomized trialAI-recommended Tier AMASH & liverSafety
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 159 · Score 103 · 2024 Jan
Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.
Diabetes, obesity & metabolism
Meta-analysisAI-recommended Tier AType 2 diabetes
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 160 · Score 103 · 2024 Mar
Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial.
Diabetes, obesity & metabolism
Meta-analysisAI-recommended Tier AWeight loss & obesity
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 161 · Score 103 · 2024 May
Anti-obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline.
Obesity reviews : an official journal of the International Association for the Study of Obesity
Meta-analysisAI-recommended Tier APediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 162 · Score 103 · 2024 Sep
Evaluating the safety profile of semaglutide: an updated meta-analysis.
Current medical research and opinion
Meta-analysisAI-recommended Tier ASafety
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 163 · Score 103 · 2024 Dec
Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis.
European journal of clinical investigation
Meta-analysisAI-recommended Tier ACardiovascular
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 164 · Score 103 · 2024 Jun 24
Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis.
Pharmaceuticals (Basel, Switzerland)
Meta-analysisAI-recommended Tier APediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 165 · Score 103 · 2024 Dec
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
Metabolism: clinical and experimental
Meta-analysisAI-recommended Tier ADiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 166 · Score 103 · 2024 Sep
Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis.
Cureus
Meta-analysisAI-recommended Tier AMASH & liver
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 167 · Score 103 · 2022 Aug
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Diabetes, obesity & metabolism
Randomized trialAI-recommended Tier ADiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 168 · Score 103 · 2022 Sep
Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.
Diabetes, obesity & metabolism
Randomized trialAI-recommended Tier AType 2 diabetes
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 169 · Score 102 · 2021 Mar 13
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Lancet (London, England)
Randomized trialAI-recommended Tier AWeight loss & obesityType 2 diabetesSafety
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 170 · Score 102 · 2021 Apr 13
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
JAMA
Randomized trialAI-recommended Tier AWeight loss & obesitySafetyDiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 171 · Score 102 · 2021 May 8
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Lancet (London, England)
Randomized trialAI-recommended Tier AWeight loss & obesitySafetyReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 172 · Score 102 · 2021 Sep
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.
The lancet. Diabetes & endocrinology
Randomized trialAI-recommended Tier AType 2 diabetesSafetyDiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 173 · Score 102 · 2023 Apr
Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis.
Diabetes research and clinical practice
Meta-analysisAI-recommended Tier AType 2 diabetesDiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 174 · Score 102 · 2023 Oct
Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.
Diabetes & metabolic syndrome
Meta-analysisAI-recommended Tier AMASH & liverSafety
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 175 · Score 102 · 2021 Mar 25
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
The New England journal of medicine
Randomized trialAI-recommended Tier AMASH & liverPediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Source registry generated 2026-09-17; AI appraisal completed 2026-09-22 under WPF-SGLT-AI-APPRAISAL-1.0. Humans resolve only the three displayed exceptions and record one accountable bundle publication decision. Records can appear in multiple domains; domain totals therefore overlap.